NS8593

An aminobenzimidazole derivative that selectively and reversibly blocks small conductance Ca2+-activated K+ channels (SK1-3; K_d = 420 nM, 600 nM, and 730 nM for SK1, SK2, SK3, respectively) in a Ca2+-dependent manner. It mediates channel gating by interacting with gating structures deep within the inner pore vestibule where Ser507 and Ala532 are deemed to be important for inhibition. Interacts at a site that is distinct from the apamin binding site in SK channels. Can access high-affinity binding sites from both the inside and outside of the cell membrane. Does not affect QT intervals, but prolongs the atrial effective refractive period and prevents acetylcholine-induced atrial fibrillations in ex vivo and in vivo models. Also shown to reversibly block TRPM7 channel (IC₅₀ = 1.6 mM) in smooth muscle cells, primary podocytes, HEK293 cells expressing TRPM7, and ventricular myocytes in a Mg2+-dependent manner and blocks the motility of cells in culture.

Packaged under inert gas

Toxicity: Standard Handling (A)

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Chubanov, V., et al. 2012. Brit. Journ. Pharm.166, 1357.
Jenkins, D., et al. 2011. Hypertension.57, 1129.
Jenkins, D., et al. 2011. Mol. Pharm.79, 899.
Jenkins, D., et al. 2011. Mol. Pharm.79, 899.
Lasse, S., et al. 2011. J. Cardiov. Pharm.57, 672.
Diness, J., et al. 2010. Circ Arrhythm Electrophusiol.3, 380.
Ji, H., et al. 2009. Eur. J. Neurosci.9, 1883.
Strobaek, D., et al. 2006. Mol. Pharm.70, 1771.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany